Mr. Brent Willis reports

VOYAGEUR PHARMACEUTICALS PUBLISHES WHITE PAPER, SMOOTHX: A PROMISING NEW POSITIVE ORAL CONTRAST AGENT THAT ENHANCES PATIENT SATISFACTION AND DIAGNOSTIC EXCELLENCE IN CT IMAGING

Voyageur Pharmaceuticals Ltd. has released the white paper titled "SmoothX: A Promising New Positive Oral Contrast Agent for CT," authored by Alec J. Megibow, MD, MPH, FACR. The white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX, emphasizing its potential to optimize abdominal CT examinations and maximize patient satisfaction.

Oral contrast agents have long been vital in elevating diagnostic accuracy and effectiveness in medical imaging procedures. With the introduction of SmoothX, Voyageur is offering a positive oral contrast agent that not only enhances diagnostic outcomes but also provides a pleasant taste, enhancing patient satisfaction.

In a recent blinded study comparing SmoothX with the established oral contrast agent Readi-CAT2, Voyageur conducted a detailed evaluation, demonstrating that SmoothX exhibited nearly identical diagnostic imaging properties. This finding establishes SmoothX as a reliable alternative that maintains the uncompromising standards of image quality required for precise diagnosis.

Of notable importance is the taste test study conducted alongside the clinical evaluation. The results revealed a remarkable preference for the palatable flavour of SmoothX among the majority of the participants compared with Readi-CAT2. This preference for SmoothX's taste has the potential to translate into heightened patient satisfaction and increased compliance during abdominal CT examinations.

Voyageur extends heartfelt appreciation to the dedicated team at Canada Diagnostic Centre in Calgary for their invaluable participation in this study. Under the exceptional leadership of Jay Zelazo, MD, FRCPC, director of CT, along with Jordan Muth, MRT (MR), MRI and CT manager, and Michelle Holstein, radiological technologist, MRT (R) (MR), the study was meticulously executed, contributing significantly to the credibility and reliability of the findings.

SmoothX represents a leap forward in oral contrast agents for CT imaging, aiming to provide a superior patient experience while ensuring optimal diagnostic outcomes. Voyageur remains steadfast in its commitment to continuous innovation, dedicated to improving the quality of care for patients worldwide.

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium, iodine and carbon active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium, iodine and carbon contrast imaging market, Voyageur aims to become a key player by producing its own barium, iodine and fullerene minerals.

The company's business plan is set to generate cash flow by partnering with established third party GMP (good manufacturing practice) pharmaceutical manufacturers in Canada, ensuring the validation of its products by regulatory agencies worldwide. As the company solidifies its presence in the market, it will transition into a high-margin domestic manufacturer of radiology drugs, further expanding its revenue streams.

Voyageur is committed to sustainability and environmental stewardship. The company envisions a future where carbon neutrality is the norm, and to achieve this, it is building state-of-the-art carbon-neutral infrastructure. By investing in carbon-neutral energy sources and sustainable manufacturing practices, Voyageur aims to become 100 per cent self-sufficient across all its manufacturing activities. The company's commitment to the environment sets it apart as a pioneer in the industry.

At the core of the company's operations, Voyageur owns a 100-per-cent interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. Additionally, Voyageur holds interests in a high-grade iodine, lithium and bromine brine project situated in Utah, United States, further bolstering its position in the industry. Voyageur owns a 100-per-cent interest in two battery mineral projects which focus on copper/zinc development.

The company's ambitious vision is to become the first vertically integrated, carbon-neutral company in the imaging contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to the final production, Voyageur plans to ensure unmatched quality and cost-efficiency. It embodies the motto of from the earth to the bottle, highlighting its commitment to responsible sourcing and manufacturing practices.

We seek Safe Harbor.